Citations (60)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Axel Ducret, Chloé Ackaert, Juliana Bessa, Campbell Bunce, Timothy Hickling, Vibha Jawa, Mark A. Kroenke, Kasper Lamberth, Anaïs Manin, Hweixian L. Penny, Noel Smith, Grzegorz Terszowski, Sophie Tourdot & Sebastian Spindeldreher. (2022) Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays. mAbs 14:1.
Read now
Read now
Martina Morelli, Marco Galluzzo, Stefania Madonna, Claudia Scarponi, Giovanni Luca Scaglione, Tiziana Galluccio, Marco Andreani, Sabatino Pallotta, Giampiero Girolomoni, Luca Bianchi, Marina Talamonti & Cristina Albanesi. (2021) HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis. Expert Opinion on Biological Therapy 21:2, pages 259-270.
Read now
Read now
Emily K. Makowski, Lina Wu, Priyanka Gupta & Peter M. Tessier. (2021) Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods. mAbs 13:1.
Read now
Read now
Robin E. Walsh, Megan Lannan, Yi Wen, Xiaoli Wang, Christopher A. Moreland, Jill Willency, Michael D. Knierman, Laura Spindler, Ling Liu, Wei Zeng, Guilherme V. Rocha, Victor Obungu, Jirong Lu, Arunan Kaliyaperumal, Andrea Ferrante, Robert Siegel & Laurent P. Malherbe. (2020) Post-hoc assessment of the immunogenicity of three antibodies reveals distinct immune stimulatory mechanisms. mAbs 12:1.
Read now
Read now
Sebastian Spindeldreher, Anette Karle, Evelyne Correia, Maxime Tenon, Sascha Gottlieb, Thomas Huber, Bernard Maillere & Frank Kolbinger. (2020) T cell epitope mapping of secukinumab and ixekizumab in healthy donors. mAbs 12:1.
Read now
Read now
Andrea Matucci, Francesca Nencini, Enrico Maggi & Alessandra Vultaggio. (2019) Hypersensitivity reactions to biologics used in rheumatology. Expert Review of Clinical Immunology 15:12, pages 1263-1271.
Read now
Read now
S. D’Adamio, D. Silvaggio, P. Lombardo, L. Bianchi, M. Talamonti & M. Galluzzo. (2019) The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. Expert Opinion on Drug Safety 18:11, pages 1031-1041.
Read now
Read now
Nobuo Sekiguchi, Chiyomi Kubo, Ayako Takahashi, Kumiko Muraoka, Akira Takeiri, Shunsuke Ito, Mariko Yano, Futa Mimoto, Atsuhiko Maeda, Yuki Iwayanagi, Tetsuya Wakabayashi, Shotaro Takata, Naoaki Murao, Shuichi Chiba & Masaki Ishigai. (2018) MHC-associated peptide proteomics enabling highly sensitive detection of immunogenic sequences for the development of therapeutic antibodies with low immunogenicity. mAbs 10:8, pages 1168-1181.
Read now
Read now
Valerie Quarmby, Qui T Phung & Jennie R Lill. (2018) MAPPs for the identification of immunogenic hotspots of biotherapeutics; an overview of the technology and its application to the biopharmaceutical arena. Expert Review of Proteomics 15:9, pages 733-748.
Read now
Read now
Wolf-Henning Boehncke & Nicolo Costantino Brembilla. (2018) Immunogenicity of biologic therapies: causes and consequences. Expert Review of Clinical Immunology 14:6, pages 513-523.
Read now
Read now
Caleb Jeon, Sahil Sekhon, Di Yan, Ladan Afifi, Mio Nakamura & Tina Bhutani. (2017) Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Human Vaccines & Immunotherapeutics 13:10, pages 2247-2259.
Read now
Read now
Yanan Cui, Ping Cui, Binlong Chen, Suxin Li & Hua Guan. (2017) Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Development and Industrial Pharmacy 43:4, pages 519-530.
Read now
Read now
Mona Malakouti, Sharon E Jacob & Nancy J Anderson. (2016) Treatment challenges in the management of moderate-to-severe plaque psoriasis – role of secukinumab. Clinical, Cosmetic and Investigational Dermatology 9, pages 347-355.
Read now
Read now
Articles from other publishers (47)
M. Violet Lee, Ola M. Saad, Sylvia Wong, Jason LaMar, Lynn Kamen, Ben Ordonia, Rachel Melendez, Azadeh Hassanzadeh, Shan Chung & Surinder Kaur. (2023) Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development. Frontiers in Immunology 14.
Crossref
Crossref
Andrea Di Ianni, Luca Barbero, Tiziana Fraone, Kyra Cowan & Federico Riccardi Sirtori. (2023) Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives. Journal of Pharmaceutical and Biomedical Analysis 234, pages 115500.
Crossref
Crossref
Sasank Konda, Nayha Shetty, Ben Friedman & Jesse Veenstra. (2023) Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa. Drug and Therapeutics Bulletin, pages dtb.2023.249684rep.
Crossref
Crossref
Oscar Pizano-Martinez, Edgar Mendieta-Condado, Mónica Vázquez-Del Mercado, Erika Aurora Martínez-García, Efrain Chavarria-Avila, Daniel Ortuño-Sahagún & Ana Laura Márquez-Aguirre. (2023) Anti-Drug Antibodies in the Biological Therapy of Autoimmune Rheumatic Diseases. Journal of Clinical Medicine 12:9, pages 3271.
Crossref
Crossref
Jeffrey D. Kearns, Paul Wassmann, Ufuk OlgacMarie Fichter, Brigitte Christen, Tina Rubic-Schneider, Stephan Koepke, Benjamin Cochin de BillyDavid Ledieu, Cedric Andre, Stuart Hawtin, Benoit Fischer, Francesca Moretti, Christian Hug, Alexander BepperlingBarbara Brannetti, Celia Mendez-Garcia, Amanda Littlewood-Evans, Andreas Clemens, Cynthia L. GrosskreutzPawan Mehan, Robert L. Schmouder, Vito Sasseville, Dominique Brees & Anette C. Karle. (2023) A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab. Science Translational Medicine 15:681.
Crossref
Crossref
Rachel Melendez, Benjamin Ordonia, Joyce Guerrero, Azadeh Hassanzadeh, Peter Tran, Justin Low, Manda Wong, Jochen Brumm, Shan Chung & Lynn Kamen. (2022) Introducing dendritic cell antibody internalization as an immunogenicity risk assessment tool. Bioanalysis 14:10, pages 703-713.
Crossref
Crossref
Sasank Konda, Nayha Shetty, Ben Friedman & Jesse Veenstra. (2022) Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa. BMJ Case Reports 15:5, pages e249684.
Crossref
Crossref
Daniel J Rader, Eleftheria Maratos-Flier, Amanda Nguyen, Doug Hom, Michael Ferriere, Yifang Li, Jill Kompa, Miljen Martic, Markus Hinder, Craig T Basson, David Yowe, John Diener, Allison B Goldfine, Archna Bajaj, Maricer Escalon, Melanie Fein, Allen Hunt, Martin K Kankam, Michael Koren, Daniel J Rader & Jessica Wilson. (2022) LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia. The Journal of Clinical Endocrinology & Metabolism 107:1, pages e57-e70.
Crossref
Crossref
Frantisek Drafi, Silvester Ponist, Bruno Sepodes & Katarina Bauerova. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
321
341
.
Sivan Cohen & Shan Chung. (2021)
In vitro
immunogenicity prediction: bridging between innate and adaptive immunity
. Bioanalysis 13:13, pages 1071-1081.
Crossref
Crossref
Katharine Bray-French, Katharina Hartman, Guido Steiner, Céline Marban-Doran, Juliana Bessa, Neil Campbell, Meret Martin-Facklam, Kay-Gunnar Stubenrauch, Corinne Solier, Thomas Singer & Axel Ducret. (2021) Managing the Impact of Immunogenicity in an Era of Immunotherapy: From Bench to Bedside. Journal of Pharmaceutical Sciences 110:7, pages 2575-2584.
Crossref
Crossref
Anders Steenholdt Attermann, Carolina Barra, Birkir Reynisson, Heidi Schiøler Schultz, Ulrike Leurs, Kasper Lamberth & Morten Nielsen. (2020) Improved prediction of HLA antigen presentation hotspots: Applications for immunogenicity risk assessment of therapeutic proteins. Immunology 162:2, pages 208-219.
Crossref
Crossref
Vibeke Strand, Joao Goncalves & John D. Isaacs. (2020) Immunogenicity of biologic agents in rheumatology. Nature Reviews Rheumatology 17:2, pages 81-97.
Crossref
Crossref
Fernando Valenzuela & Rodrigo Flores. (2021) Immunogenicity to biological drugs in psoriasis and psoriatic arthritis. Clinics 76, pages e3015.
Crossref
Crossref
Daniela Di Blasi, Iris Claessen, Annelies W. Turksma, Josine van Beek & Anja ten Brinke. (2020) Guidelines for analysis of low-frequency antigen-specific T cell results: Dye-based proliferation assay vs 3H-thymidine incorporation. Journal of Immunological Methods 487, pages 112907.
Crossref
Crossref
Guido Steiner, Céline Marban-Doran, Jessica Langer, Tatiana Pimenova, Gonzalo Duran-Pacheco, Denise Sauter, Anja Langenkamp, Corinne Solier, Thomas Singer, Katharine Bray-French & Axel Ducret. (2020) Enabling Routine MHC-II-Associated Peptide Proteomics for Risk Assessment of Drug-Induced Immunogenicity. Journal of Proteome Research 19:9, pages 3792-3806.
Crossref
Crossref
Sabrina Ching Tung Wong & Ho Yin Chung. (2020) Secukinumab-Induced Delayed-Type Drug Hypersensitivity Reactions. JCR: Journal of Clinical Rheumatology 26:6, pages e197-e198.
Crossref
Crossref
Jin-Ock Kim, Ha-Neul Kim, Kwang-Hyeok Kim, Eun Ji Baek, Jeong-Yang Park, Kyungsoo Ha, Deok Rim Heo, Min-Duk Seo & Sang Gyu Park. (2020) Development and characterization of a fully human antibody targeting SCF/c-kit signaling. International Journal of Biological Macromolecules 159, pages 66-78.
Crossref
Crossref
Anna Vaisman-Mentesh, Matias Gutierrez-Gonzalez, Brandon J. DeKosky & Yariv Wine. (2020) The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies. Frontiers in Immunology 11.
Crossref
Crossref
Vibha Jawa, Frances Terry, Jochem Gokemeijer, Shibani Mitra-Kaushik, Brian J. Roberts, Sophie Tourdot & Anne S. De Groot. (2020) T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020. Frontiers in Immunology 11.
Crossref
Crossref
Carolina Barra, Chloe Ackaert, Birkir Reynisson, Jana Schockaert, Leon Eyrich Jessen, Mark Watson, Anne Jang, Simon Comtois-Marotte, Jean-Philippe Goulet, Sofie Pattijn, Eustache Paramithiotis & Morten Nielsen. (2020) Immunopeptidomic Data Integration to Artificial Neural Networks Enhances Protein-Drug Immunogenicity Prediction. Frontiers in Immunology 11.
Crossref
Crossref
Brian R. Duke & Shibani Mitra-Kaushik. (2019) Current In Vitro Assays for Prediction of T Cell Mediated Immunogenicity of Biotherapeutics and Manufacturing Impurities. Journal of Pharmaceutical Innovation 15:2, pages 202-218.
Crossref
Crossref
Anette C. Karle. (2020) Applying MAPPs Assays to Assess Drug Immunogenicity. Frontiers in Immunology 11.
Crossref
Crossref
Atul Deodhar, Dafna D. Gladman, Iain B. McInnes, Sebastian Spindeldreher, Ruvie Martin, Luminita Pricop, Brian Porter, Jorge SafiJr.Jr., Abhijit Shete & Gerard Bruin. (2020) Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. The Journal of Rheumatology 47:4, pages 539-547.
Crossref
Crossref
Maurizio Benucci, Valentina Grossi, Mariangela Manfredi, Arianna Damiani, Maria Infantino, Paolo Moscato, Luigi Cinquanta, Elisa Gremese, Barbara Tolusso, Luca Petricca, Anna Laura Fedele, Stefano Alivernini, Fabiola Atzeni, Giovanni Minisola & Roberto Verna. (2020) Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. Annals of Laboratory Medicine 40:2, pages 101-113.
Crossref
Crossref
L.J. Vugt, J.M.P.A. Reek, E. Meulewaeter, M. Hakobjan, N. Heddes, T. Traks, K. Kingo, M. Galluzzo, M. Talamonti, J. Lambert, M.J.H. Coenen & E.M.G.J. Jong. (2019)
Response to
IL
‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the
IL
‐17A gene: results from a multicentre study of four European psoriasis cohorts
. Journal of the European Academy of Dermatology and Venereology 34:1, pages 112-118.
Crossref
Crossref
Osman N. Yogurtcu, Zuben E. Sauna, Joseph R. McGill, Million A. Tegenge & Hong Yang. (2019) TCPro: an In Silico Risk Assessment Tool for Biotherapeutic Protein Immunogenicity. The AAPS Journal 21:5.
Crossref
Crossref
Lora Hamuro, Giridhar S. Tirucherai, Sean M. Crawford, Akbar Nayeem, Renuka C. Pillutla, Binodh S. DeSilva, Tarek A. Leil & Craig J. Thalhauser. (2019) Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1. The AAPS Journal 21:5.
Crossref
Crossref
K. Reich, A. Blauvelt, A. Armstrong, R.G. Langley, A. de Vera, F. Kolbinger, S. Spindeldreher, M. Ren & G. Bruin. (2019) Secukinumab, a fully human anti‐interleukin‐17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. Journal of the European Academy of Dermatology and Venereology 33:9, pages 1733-1741.
Crossref
Crossref
Shivani B. Kaushik & Mark G. Lebwohl. (2018) Review of safety and efficacy of approved systemic psoriasis therapies. International Journal of Dermatology 58:6, pages 649-658.
Crossref
Crossref
Asmah Johar, Suganthi Thevarajah, Agnes Heng, Lee Chin Chan, Chin Chwen Ch’ng, Najeeb Ahmad Mohd Safdar, Pubalan Muniandy, Tarita Taib, Wooi Chiang Tan & Kwee Eng Tey. (2019) Position Statement on Secukinumab in the Management of Plaque Psoriasis: The Malaysian Perspective. Dermatology Research and Practice 2019, pages 1-8.
Crossref
Crossref
Robert Dingman & Sathy V. Balu-Iyer. (2019) Immunogenicity of Protein Pharmaceuticals. Journal of Pharmaceutical Sciences 108:5, pages 1637-1654.
Crossref
Crossref
Floriane Groell, Olivier Jordan & Gerrit Borchard. (2018) In vitro models for immunogenicity prediction of therapeutic proteins. European Journal of Pharmaceutics and Biopharmaceutics 130, pages 128-142.
Crossref
Crossref
Sebastian Spindeldreher, Bernard Maillère, Evelyne Correia, Maxime Tenon, Anette Karle, Philip Jarvis & Frank Kolbinger. (2018) Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab. Dermatology and Therapy 8:1, pages 57-68.
Crossref
Crossref
Sandor Kerpel-Fronius. (2018) A short review of the pharmacokinetic behavior of biological medicinal agents for the clinical practice. Microchemical Journal 136, pages 270-274.
Crossref
Crossref
Frank R. Brennan & Andrea Kiessling. (2017) In vitro assays supporting the safety assessment of immunomodulatory monoclonal antibodies. Toxicology in Vitro 45, pages 296-308.
Crossref
Crossref
Laetitia Sordé, Sebastian Spindeldreher, Ed Palmer & Anette Karle. (2017) Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?. Immunity, Inflammation and Disease 5:4, pages 400-415.
Crossref
Crossref
Carolina M. Pfaff, Yvonne Marquardt, Katharina Fietkau, Jens M. Baron & Bernhard Lüscher. (2017) The psoriasis-associated IL-17A induces and cooperates with IL-36 cytokines to control keratinocyte differentiation and function. Scientific Reports 7:1.
Crossref
Crossref
Jochem Gokemeijer, Vibha Jawa & Shibani Mitra-Kaushik. (2017) How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective. The AAPS Journal 19:6, pages 1587-1592.
Crossref
Crossref
M.F. Peigottu & M.A. Montesu. (2017) Adverse skin reaction to Secukinumab. Journal of the European Academy of Dermatology and Venereology 31:10, pages e432-e433.
Crossref
Crossref
Jennie R. Lill. 2017. Analytical Characterization of Biotherapeutics. Analytical Characterization of Biotherapeutics
1
14
.
Heidi S. Schultz, Stine Louise Reedtz-Runge, B. Thomas Bäckström, Kasper Lamberth, Christian R. Pedersen & Anne M. Kvarnhammar. (2017) Quantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assay. PLOS ONE 12:5, pages e0178544.
Crossref
Crossref
Moustafa Hamze, Sylvain Meunier, Anette Karle, Abdelaziz Gdoura, Amélie Goudet, Natacha Szely, Marc Pallardy, Franck Carbonnel, Sebastian Spindeldreher, Xavier Mariette, Corinne Miceli-Richard & Bernard Maillère. (2017) Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors. Frontiers in Immunology 8.
Crossref
Crossref
K. Reich, A. BlauveltA. ArmstrongR.G. Langley, T. Fox, J. HuangC. Papavassilis, E. Liang, P. Lloyd & G. Bruin. (2017) Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology 176:3, pages 752-758.
Crossref
Crossref
Frances-Rose Schumacher, Lélia Delamarre, Suchit Jhunjhunwala, Zora Modrusan, Qui T. Phung, Joshua E. Elias & Jennie R. Lill. (2017) Building proteomic tool boxes to monitor MHC class I and class II peptides. PROTEOMICS 17:1-2, pages 1600061.
Crossref
Crossref
Guenter Blaich, Andreas Baumann, Sven Kronenberg, Lolke de Haan, Peter Ulrich, Wolfgang F. Richter, Jay Tibbitts, Simon Chivers, Edit Tarcsa, Robert Caldwell & Flavio Crameri. (2016) Non-clinical Safety Evaluation of Biotherapeutics ? Challenges, Opportunities and new Insights. Regulatory Toxicology and Pharmacology 80, pages S1-S14.
Crossref
Crossref
Anshu Kuriakose, Narendra Chirmule & Pradip Nair. (2016) Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. Journal of Immunology Research 2016, pages 1-18.
Crossref
Crossref